Oppenheimer & Co. Inc. Acquires New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Oppenheimer & Co. Inc. acquired a new stake in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 17,850 shares of the company’s stock, valued at approximately $311,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PLSE. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares during the last quarter. State Street Corp increased its stake in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after acquiring an additional 69,696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pulse Biosciences in the 3rd quarter worth about $588,000. Geode Capital Management LLC increased its stake in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares during the last quarter. Finally, Barclays PLC increased its stake in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after acquiring an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Insider Transactions at Pulse Biosciences

In related news, Director Robert W. Duggan bought 55,256 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now directly owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 71.50% of the company’s stock.

Pulse Biosciences Trading Up 2.7 %

PLSE opened at $17.37 on Friday. The stock has a 50-day moving average price of $19.31 and a 200-day moving average price of $18.42. Pulse Biosciences, Inc. has a 12-month low of $6.59 and a 12-month high of $25.00.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.